Improving attribution of adverse events in oncology clinical trials

被引:16
|
作者
George, Goldy C. [1 ]
Barata, Pedro C. [2 ]
Campbell, Alicyn [3 ]
Chen, Alice [4 ]
Cortes, Jorge E. [5 ]
Hyman, David M. [6 ,11 ]
Jones, Lee
Karagiannis, Thomas [7 ]
Klaar, Sigrid [8 ]
Le-Rademacher, Jennifer G. [9 ]
LoRusso, Patricia [10 ]
Mandrekar, Sumithra J. [9 ]
Merino, Diana M. [11 ]
Minasian, Lori M. [4 ]
Mitchell, Sandra A. [12 ]
Montez, Sandra [5 ]
O'Connor, Daniel J. [13 ]
Pettit, Syril [14 ]
Silk, Elaine
Sloan, Jeff A. [9 ]
Stewart, Mark [4 ]
Takimoto, Chris H. [15 ]
Wong, Gilbert Y. [16 ]
Yap, Timothy A. [5 ]
Cleeland, Charles S. [5 ]
Hong, David S. [5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr MD Anderson, Houston, TX USA
[2] Tulane Univ, New Orleans, LA 70118 USA
[3] Genentech Inc, San Francisco, CA USA
[4] NCI, Bethesda, MD 20892 USA
[5] MD Anderson, Houston, TX USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Genentech Inc, Chicago, IL USA
[8] Swedish Med Prod Agcy, Uppsala, Sweden
[9] Mayo Clin, Rochester, MN USA
[10] Yale Univ, Canc Ctr, New Haven, CT USA
[11] Friends Canc Res, Washington, DC USA
[12] NCI, Rockville, MD USA
[13] Med & Healthcare Prod Regulatory Agcy, London, England
[14] Hlth & Environm Sci Inst, Washington, DC USA
[15] Forty Seven Inc, Menlo Pk, CA USA
[16] Pfizer, New York, NY USA
关键词
Attribution; Adverse event; Clinical trial; Cancer treatment; Toxicity; Symptom; PATIENT-REPORTED OUTCOMES; PHASE-I TRIALS; CANCER-TREATMENT; SAFETY; TOXICITIES; SPONSORS; QUALITY; TIME;
D O I
10.1016/j.ctrv.2019.04.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Attribution of adverse events (AEs) is critical to oncology drug development and the regulatory process. However, processes for determining the causality of AEs are often sub-optimal, unreliable, and inefficient. Thus, we conducted a toxicity-attribution workshop in Silver Springs MD to develop guidance for improving attribution of AEs in oncology clinical trials. Attribution stakeholder experts from regulatory agencies, sponsors and contract research organizations, clinical trial principal investigators, pre-clinical translational scientists, and research staff involved in capturing attribution information participated. We also included patients treated in oncology clinical trials and academic researchers with expertise in attribution. We identified numerous challenges with AE attribution, including the non-informative nature of and burdens associated with the 5-tier system of attribution, increased complexity of trial logistics, costs and time associated with AE attribution data collection, lack of training in attribution for early-career investigators, insufficient baseline assessments, and lack of consistency in the reporting of treatment-related and treatment-emergent AEs in publications and clinical scientific reports. We developed recommendations to improve attribution: we propose transitioning from the present 5-tier system to a 2-3 tier system for attribution, more complete baseline information on patients' clinical status at trial entry, and mechanisms for more rapid sharing of AE information during trials. Oncology societies should develop recommendations and training in attribution of toxicities. We call for further harmonization and synchronization of recommendations regarding causality safety reporting between FDA, EMA and other regulatory agencies. Finally, we suggest that journals maintain or develop standardized requirements for reporting attribution in oncology clinical trials.
引用
收藏
页码:33 / 40
页数:8
相关论文
共 50 条
  • [1] A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials
    Mukherjee, Som D.
    Coombes, Megan E.
    Levine, Mitch
    Cosby, Jarold
    Kowaleski, Brenda
    Arnold, Andrew
    [J]. INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1013 - 1020
  • [2] A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials
    Som D. Mukherjee
    Megan E. Coombes
    Mitch Levine
    Jarold Cosby
    Brenda Kowaleski
    Andrew Arnold
    [J]. Investigational New Drugs, 2011, 29 : 1013 - 1020
  • [3] Analysis of adverse events attribution and reporting in cancer clinical trials: A systematic review
    Enrico, Diego
    Waisberg, Federico
    Burton, Jeannette
    Mando, Pablo
    Chacon, Matias
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
  • [4] A new method to analyze adverse events longitudinally in oncology clinical trials.
    Thanarajasingam, Gita
    Novotny, Paul J.
    Loprinzi, Charles L.
    Grothey, Axel
    Atherton, Pamela J.
    Sloan, Jeff A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] A tool for assessing adverse events in phase I/II oncology clinical trials
    Coombes, M.
    Mukherjee, S.
    Kowaleski, B.
    Levine, M.
    Cosby, J.
    Arnold, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Adverse events in exercise oncology: How safe is training outside of clinical trials?
    Clauss, Dorothea
    Quirmbach, Franziska
    Wiskemann, Joachim
    Rosenberger, Friederike
    [J]. BEWEGUNGSTHERAPIE UND GESUNDHEITSSPORT, 2019, 35 (04): : 194 - 201
  • [7] Clinical trials on adverse events of therapy
    Alonso, Miguel Araujo
    [J]. MEDWAVE, 2011, 11 (09):
  • [8] Adverse event development in clinical oncology trials
    Schmoor, Claudia
    Bender, Ralf
    Beyersmann, Jan
    Kieser, Meinhard
    Schumacher, Martin
    [J]. LANCET ONCOLOGY, 2016, 17 (07): : E263 - E264
  • [9] Adverse events reporting in phase 3 oncology clinical trials of checkpoint inhibitors: A systematic review
    Barhli, Aline
    Joulia, Marie-Liesse
    Tournigand, Christophe
    Kempf, Emmanuelle
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
  • [10] Adverse Events Reporting of Clinical Trials in Exercise Oncology Research (ADVANCE): Protocol for a Scoping Review
    Luo, Hao
    Schumacher, Oliver
    Galvao, Daniel A.
    Newton, Robert U.
    Taaffe, Dennis R.
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12